Skip to main content

  1 Baseline characteristics and clinical data

From: Early and late recurrence after hepatectomy in patients with low-level HBV-DNA hepatocellular carcinoma under antiviral therapy

 

Non-antiviral group, n = 139

Antival group, n = 157

p value

Age, years

56 (49–65)

57 (49–65)

0.722

Male sex, n (%)

115 (82.7)

127 (80.9)

0.682

ALT, IU/m

35 (25–54)

35 (26–51)

0.760

AST, IU/ml

37 (28–56)

40 (30–61.5)

0.494

ALP, IU/L

93 (75-140.5)

96 (73.5–119)

0.462

ALB, g/L

40.5 (36.9–43.2)

39.5 (36.0–42.6)

0.159

Total bilirubin, µmol/L

17.2 (14.1–25.0)

17.9 (13.6–23.5)

0.544

PT, s

11.4 (10.8–12.2)

11.5 (11.0–12.35)

0.236

AFP, ng/ml

8.1 (2.8-310.1)

156.3 (16.5–1038.8)

< 0.001

PLT, 109/L

95 (88–183)

97 (92.5–207)

0.026

Satellite nodules, n (%)

17 (12.2)

29 (18.5)

0.139

Capsular, n (%)

107 (77.0)

126 (80.2)

0.492

Moderate/poor tumor differentiation, n (%)

54 (38.8)

57 (36.3)

0.652

Vascular invasion, n (%)

42 (30.2)

23 (14.6)

0.001

Tumor size, cm

6 (3.5–7.0)

5 (3–8)

0.199

Multiple tumor, n (%)

22 (15.8)

22 (14.0)

0.363

Cirrhosis, n (%)

95 (68.3)

101 (64.3)

0.466

Hypertension, n (%)

40 (28.8)

39 (24.8)

0.445

Diabetes mellitus, n (%)

26 (18.7)

26 (16.6)

0.628

History of smoking, n (%)

55 (39.6)

62 (39.5)

0.989

Alcohol abuse, n (%)

54 (38.8)

52 (33.1)

0.305

HBeAg positive, n (%)

27 (19.4)

24 (15.2)

0.347

Child–Pugh score

  

0.135

 A

135

156

 

 B

4

1

 

BCLC stage

  

0.005

 Very early (0)

10

17

 

 Early (A)

38

61

 

 Intermediate (B)

48

56

 

 Advanced (C)

43

23

Â